| 1.6 -0.14 (-8.05%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.7 |
1-year : | 4.94 |
| Resists | First : | 3.16 |
Second : | 4.23 |
| Pivot price | 3.2 |
|||
| Supports | First : | 1.45 | Second : | 1.2 |
| MAs | MA(5) : | 2.56 |
MA(20) : | 3.3 |
| MA(100) : | 4.08 |
MA(250) : | 7.56 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.2 |
D(3) : | 26.5 |
| RSI | RSI(14): 27.7 |
|||
| 52-week | High : | 23.45 | Low : | 1.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TBIO ] has closed below the lower bollinger band by 1.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ TBIO ] is to continue within current trading range. It is unclear right now based on current values. 78.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.53 - 1.54 | 1.54 - 1.55 |
| Close: | 1.58 - 1.6 | 1.6 - 1.61 |
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Thu, 12 Sep 2024
TBIO - Telesis Bio, Inc. Latest Stock News & Market Updates - StockTitan
Tue, 10 Sep 2024
Telesis Bio to delist from Nasdaq by end of September - Investing.com
Tue, 10 Sep 2024
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market - StockTitan
Thu, 05 Sep 2024
Telesis Bio (NASDAQ:TBIO) Trading Up 3.8% - Defense World
Wed, 28 Aug 2024
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Mon, 06 May 2024
Telesis Bio Implements Reverse Stock Split, Elects Directors - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 37.9 (%) |
| Held by Institutions | 32.9 (%) |
| Shares Short | 25 (K) |
| Shares Short P.Month | 51 (K) |
| EPS | -30.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -11.6 |
| Profit Margin | -253.2 % |
| Operating Margin | -675.8 % |
| Return on Assets (ttm) | -26.6 % |
| Return on Equity (ttm) | -147.9 % |
| Qtrly Rev. Growth | -78 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 11.05 |
| EBITDA (p.s.) | -18.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | -0.14 |
| Price to Sales | 0.14 |
| Price to Cash Flow | -0.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|